Disentangling minimum clinically important difference for an individual and a population in the treatment of Alzheimer's disease.

ABSTRACT: Recent accelerated and traditional approval of anti-amyloid therapies by the U.S. Food and Drug Administration for the treatment of patients with early Alzheimer's disease has stimulated heated debate on whether or not the benefits of these therapeutic agents achieve a minimum clinically important effect size, or minimum clinically important difference. We argue that these debates are rooted in the entanglement of two fundamentally different concepts, the minimum clinically important difference for an individual versus that of a population. At the core of the indiscrimination between the two concepts is the unrealistic requirement or expectation that a drug should provide the same clinically important effect for every patient in the target population to be considered achieving meaningful b

SUBMITTER: Shen C 

PROVIDER: S-EPMC12075744 | biostudies-literature | 2025 Apr-Jun

REPOSITORIES: biostudies-literature